2015 Global Survey on Liquid Biopsy Adoption Trends

Learn the Promising Technologies and Bottlenecks for CTCs and ctDNA--A Voice of Customer Study

Feb 11, 2016, 17:54 ET from ReportBuyer

LONDON, Feb. 11, 2016 /PRNewswire/ -- The primary goal of this research is to analyze the current and future adoption patterns on the usage of liquid biopsy. Key information the survey seeks to collect include the following:

- Current and future use of liquid biopsy by organization type
- Timeframe of liquid biopsy adoption amidst future users
- Predominantly used cell types—CTCs, ctDNA, cfDNA and Evs—by organization type
- Sample inflow to conduct liquid biopsy tests
- Preference for sample types: blood, saliva, stool, serum, and so on.
- Correlation analysis of sample type and biomarker type
- Promising applications for liquid biopsy—current and future
- Predominant approaches to liquid biopsy: hotspot panels, single marker tests, and so on
- Technologies used to detect CtDNA—current vs. future users
- Technologies used to detect CTCs
- Vendor popularity for specific biomarkers and reimbursement scenario
- Bottlenecks to mainstream implementation of liquid biopsy

Research Objectives
The primary goal of this research is to analyze the current and future adoption patterns on the usage of liquid biopsy. Key information the survey seeks to collect include the following:
- Current and future use of liquid biopsy by organization type
- Timeframe of liquid biopsy adoption amidst future users
- Predominantly used cell types—CTCs, ctDNA, cfDNA and EVs—by organization type
- Sample inflow to conduct liquid biopsy tests
- Preference for sample types: blood, saliva, stool, serum, and so on.
- Correlation analysis of sample type and biomarker type
- Promising applications for liquid biopsy—current and future
- Predominant approaches to liquid biopsy: hotspot panels, single marker tests, and so on
- Technologies used to detect ctDNA—current vs. future users
- Technologies used to detect CTCs
- Vendor popularity for specific biomarkers and reimbursement scenario
- Bottleneck to mainstream implementation of liquid biopsy

Research Methodology

Methodology
Clinical and Research Laboratories were invited to participate in an online survey in July 2015. To qualify for survey participation, respondents must work within a private or public laboratory, academic research facility, hospital lab or a pharmaceutical or diagnostic company that employs liquid biopsy technologies. Respondents should be a constant user of liquid biopsy technologies, belong to the scientific community, and be in a position to authorize purchases and handle laboratory budgets.

Sample
The target group was screened to ensure only qualified respondents participated. In total, decision makers qualified for the survey, representing the following types of laboratories:

Pharmaceutical and diagnostic companies
Research institutes and universities
Hospital laboratories
Reference laboratories (includes CLIA-/CAP-certified laboratories)

Reporting Notes
- Respondents indicated a wide range of job titles, such as lab directors, scientists, lab managers, oncologists, clinicians, pathologists, and lab technicians.
- In total, about % of respondents work in the United States, and about % work in Europe. Nevertheless, this study is considered global because the survey was open to respondents from all countries.
- Due to rounding, percentages in charts and tables may not sum to.

Download the full report: https://www.reportbuyer.com/product/3365810/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer



RELATED LINKS

http://www.reportbuyer.com